Research Papers:

The serum activity of thioredoxin reductases 1 (TrxR1) is correlated with the poor prognosis in EGFR wild-type and ALK negative non-small cell lung cancer

Gong Chen, Qiong Chen, Fanxu Zeng, Liang Zeng, Haiyan Yang, Yi Xiong, Chunhua Zhou, Li Liu, Wenjuan Jiang, Nong Yang and Yongchang Zhang _

PDF  |  HTML  |  How to cite

Oncotarget. 2017; 8:115270-115279. https://doi.org/10.18632/oncotarget.23252

Metrics: PDF 1214 views  |   HTML 3085 views  |   ?  


Gong Chen1,*, Qiong Chen1,*, Fanxu Zeng1, Liang Zeng1, Haiyan Yang1, Yi Xiong1, Chunhua Zhou1, Li Liu1, Wenjuan Jiang1, Nong Yang1 and Yongchang Zhang1

1Departement of Medical Oncology, Lung Cancer and Gastrointestinal Unit, Hunan Cancer Hospital/Affiliated Cancer Hospital of Xiangya School of Medicine, Changsha 410013, China

*These authors have contributed equally to this work

Correspondence to:

Yongchang Zhang, email: [email protected]

Nong Yang, email: [email protected]

Keywords: thioredoxin reductases 1; bio-marker; EGFR wild type and ALK negative non-small-cell lung cancer; CEA; prognosis

Received: July 29, 2017     Accepted: December 04, 2017     Published: December 14, 2017


Background: The thioredxin reductases 1 (TrxR1) is one of the major antioxidant and redox regulators in mammalian cells. Studies have shown that TrxR1 is over expressed in many malignancy diseases. However, few studies have evaluated the role of TrxR1 in non-small cell lung cancer (NSCLC).

Methods: Serum levels of TrxR1 and CEA in 142 patients with EGFR wild type and ALK negative advanced NSCLC was measured by ELISA assay before first line standard doublet chemotherapy from June 2013 to February 2016 in Hunan Cancer Hospital. Clinical characteristics and Survival data were collected and analyzed according to serum TrxR1 levels.

Results: No significant differences were founded from clinic pathological variables. With the cut-off value of 12U/mL, the lower serum TrxR1 activity patients had long progression-free survival (PFS) and overall survival (OS) compared with higher patients (PFS: 5.3m vs. 3.6m p=0.044, OS: 14.5m vs. 11m p<0.001). In subgroup, lower serum TrxR1 activity patients had long OS both in adenocarcinoma (ADC) (17m vs. 8m, p=0.003) and squamous cell carcinoma (SCC) (13m vs. 11m, p=0.035). While combining with TrxR1 activity and serum CEA concentrations, we founded that patients with lower serum TrxR1 activity and serum CEA concentrations had long OS compared with higher group patients (20m vs. 7m, p<0.001).

Conclusions: Serum TrxR1 activity was not affected by clinic pathological variables. Measurement of serum TrxR1 activity might be an independent prognostic factor for EGFR wild type and ALK negative advanced NSCLC patients. Combination of serum TrxR1 activity and serum CEA concentrations need to be further profiled from bench to beside.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 23252